Status:
RECRUITING
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University
Conditions:
Cervical Cancer
Immunochemotherapy
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility Criteria
Inclusion
- Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
- Positive PD-L1 expression;
- ECOG score ≤1
Exclusion
- Positive parametrium or surgical margin;
- Incomplete radical surgery;
- Residual target lesions;
- Active autoimmune disease or autoimmune disease requiring systemic treatment;
- Previous treatment with immune checkpoint inhibitors.
Key Trial Info
Start Date :
March 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT07167160
Start Date
March 10 2025
End Date
December 31 2029
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310000